Clinical trial

Bicarbonate Administration and Cognitive Function in Midlife and Older Adults With CKD

Name
20-1672
Description
This is a pilot, randomized, double-blinded, placebo-controlled, 12-month trial of 50 patients with CKD stage 3b-4 with metabolic acidosis to examine the effect of sodium bicarbonate therapy on cognitive and cerebrovascular function.
Trial arms
Trial start
2021-02-01
Estimated PCD
2023-08-30
Trial end
2023-08-30
Status
Completed
Phase
Early phase I
Treatment
Sodium Bicarbonate Tablets
Participants will be given sodium bicarbonate at 0.5 mEq/kg-LBW/day for 12 months
Arms:
Sodium bicarbonate
Placebo
Participants will be given placebo at 0.5 mEq/kg-LBW/day for 12 months
Arms:
Placebo
Size
34
Primary endpoint
Change in Cognitive Function at 12 months
Baseline and 12 months
Change in Cognitive Function composite score at 12 months
baseline and 12 months
Change in Fluid Cognition Composite Score at 12 months
baseline and 12 months
Change in Crystallized cognition composite score at 12 months
baseline and 12 months
Eligibility criteria
Inclusion Criteria: * Age 50-75 years old * Serum bicarbonate 16-22 mEq/L on 2 separate measurements (at least 1 day apart) * CKD stage 3b or 4 at time of screening (eGFR 15-44 ml/min/1.73m2) * Blood pressure \<130/80 mm Hg prior to randomization * Use of angiotensin converting enzyme inhibitor or angiotensin receptor blocker * Stable anti-hypertensive regimen for at least one month prior to randomization * Montreal Cognitive Assessment Score \> 24 * No history of stroke * No history of dementia * No history of neurologic disease * Able to provide consent Exclusion Criteria:• Significant comorbid conditions that lead the investigator to conclude that life expectancy is less than 1 year * Use of chronic daily oral alkali within the last 3 months (including sodium bicarbonate, calcium carbonate or baking soda) * Uncontrolled hypertension * Serum potassium \< 3.3 or ≥ 5.5 mEq/L at screening * New York Heart Association Class 3 or 4 heart failure symptoms, known EF ≤30%, or hospital admission for heart failure within the past 3 months * Factors judged to limit adherence to interventions * Anticipated initiation of dialysis or kidney transplantation within 12 months * Current participation in another research study * Pregnancy or planning to become pregnant or currently breastfeeding * Chronic use of supplemental oxygen
Protocol
{'studyType': 'INTERVENTIONAL', 'phases': ['EARLY_PHASE1'], 'designInfo': {'allocation': 'RANDOMIZED', 'interventionModel': 'PARALLEL', 'primaryPurpose': 'TREATMENT', 'maskingInfo': {'masking': 'QUADRUPLE', 'whoMasked': ['PARTICIPANT', 'CARE_PROVIDER', 'INVESTIGATOR', 'OUTCOMES_ASSESSOR']}}, 'enrollmentInfo': {'count': 34, 'type': 'ACTUAL'}}
Updated at
2024-05-08

1 organization

1 product

1 drug

3 indications